| __timestamp | Viking Therapeutics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1244910 | 7751000 |
| Thursday, January 1, 2015 | 5029636 | 10251000 |
| Friday, January 1, 2016 | 4846776 | 9575000 |
| Sunday, January 1, 2017 | 5329003 | 10912000 |
| Monday, January 1, 2018 | 7121000 | 11049000 |
| Tuesday, January 1, 2019 | 9128000 | 11646000 |
| Wednesday, January 1, 2020 | 10731000 | 13265000 |
| Friday, January 1, 2021 | 10701000 | 25805000 |
| Saturday, January 1, 2022 | 16121000 | 35182000 |
| Sunday, January 1, 2023 | 37021000 | 94999000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Viking Therapeutics, Inc. and Viridian Therapeutics, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, Viking's SG&A expenses grew steadily, peaking at $37 million in 2023, a nearly 30-fold increase from 2014. Meanwhile, Viridian's expenses surged to $95 million in 2023, marking a 12-fold rise. Despite Viridian's higher absolute costs, Viking's expenses grew at a faster rate, indicating aggressive expansion or increased operational costs. Investors should consider these trends when evaluating the companies' financial strategies. While Viridian's higher expenses might suggest robust growth, Viking's rapid increase could signal strategic investments or inefficiencies. Understanding these dynamics is key to making informed investment decisions in the biotech sector.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Amgen Inc. vs Viridian Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Sanofi or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and Viking Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Viridian Therapeutics, Inc.
Incyte Corporation and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Viking Therapeutics, Inc. and MorphoSys AG
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs ImmunityBio, Inc. Trends and Insights
Viking Therapeutics, Inc. and Evotec SE: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Mesoblast Limited vs Viridian Therapeutics, Inc.